Candel Therapeutics Inc (NASDAQ:CADL) — Market Cap & Net Worth
Market Cap & Net Worth: Candel Therapeutics Inc (CADL)
Candel Therapeutics Inc (NASDAQ:CADL) has a market capitalization of $597.89 Million ($597.89 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11371 globally and #2941 in its home market, demonstrating a -12.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Candel Therapeutics Inc's stock price $11.02 by its total outstanding shares 73270239 (73.27 Million). Also see CADL asset base for a full breakdown of the balance sheet.
Candel Therapeutics Inc Market Cap History: 2021 to 2026
Candel Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows growth from $572.97 Million to $807.44 Million (9.23% CAGR). Also see Candel Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Candel Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #317 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1157 of 3165 |
Weight: Candel Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Candel Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Candel Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Candel Therapeutics Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3474.43x
Candel Therapeutics Inc's market cap is 3474.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $572.97 Million | $125.00K | -$36.12 Million | 4583.79x | N/A |
| 2022 | $131.15 Million | $125.00K | -$18.79 Million | 1049.23x | N/A |
| 2023 | $107.71 Million | $31.00K | -$37.94 Million | 3474.43x | N/A |
Competitor Companies of CADL by Market Capitalization
Companies near Candel Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review CADL tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Candel Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Candel Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Candel Therapeutics Inc's market cap moved from $572.97 Million to $ 807.44 Million, with a yearly change of 9.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $807.44 Million | +95.04% |
| 2025 | $413.98 Million | -34.91% |
| 2024 | $635.99 Million | +490.48% |
| 2023 | $107.71 Million | -17.88% |
| 2022 | $131.15 Million | -77.11% |
| 2021 | $572.97 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Candel Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $597.89 Million USD |
| MoneyControl | $597.89 Million USD |
| MarketWatch | $597.89 Million USD |
| marketcap.company | $597.89 Million USD |
| Reuters | $597.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more